Trials / Active Not Recruiting
Active Not RecruitingNCT05811416
A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
Observational, Multicenter Study to Describe the Persistence in Relapsing Remitting Multiple Sclerosis Naive Patients With Low-moderate Activity Treated With Ozanimod (Zeposia®) in Clinical Practice in Spain
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to collect clinical data on the persistence with ozanimod treatment, as well as to describe its effects on participant-relevant outcome parameters in treatment-naïve participants with RRMS.
Conditions
Timeline
- Start date
- 2023-06-14
- Primary completion
- 2026-11-09
- Completion
- 2026-11-09
- First posted
- 2023-04-13
- Last updated
- 2025-11-24
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT05811416. Inclusion in this directory is not an endorsement.